Skip to main content

Cyclophosphamide News

Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia

MONDAY, June 24, 2024 – For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD)...

Strategy with Cyclophosphamide Could Expand Stem Cell Donor Pool for People Battling Blood Cancers

TUESDAY, May 28, 2024 – An older drug used in a new way could open the path for more patients with potentially deadly blood cancers to receive a lifesaving stem cell transplant, a new study finds....

Genmab Announces U.S. FDA Approval of Arzerra (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL

Copenhagen, Denmark; August 31, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Non-Small Cell Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Multiple Sclerosis, Prostate Cancer, Rheumatoid Arthritis, Small Cell Lung Cancer, Multiple Myeloma, Breast Cancer, view more... Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Systemic Lupus Erythematosus

Cyclophosphamide patient information at Drugs.com